Press release - 09/09/2022 Breaking down proteins: How starving cancer cells switch food sources Cancer cells often grow in environments that are low in nutrients, and they cope with this challenge by switching their metabolism to using proteins as alternative "food". Building on genetic screens, an international team of scientists could identify the protein LYSET as part of a pathway that allows cancer cells to make this switch. Their findings are now published in the journal Science.
Press release - 06/09/2022 Biointelligent sensor for measuring viral activity Today, genome editing is almost as easy as programming software. However, the generation of viral vectors as initial material is still associated with many expensive and error-prone handling procedures. Viruses are generated via complex biological processes that have to be optimised virus-specifically in order to produce high-quality therapeutics. A new method is needed that simplifies and optimises these processes.
Press release - 01/09/2022 Personalised antibiotic treatment strategies for tuberculosis patients Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.
Press release - 31/08/2022 Using nanopores to detect epigenetic changes faster Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.
Press release - 18/08/2022 CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on mRNA, today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.
Press release - 18/08/2022 When smooth muscle cells lack strength University of Tübingen team discovers how malformations of the blood vessels can occur in mice – yielding information with possible ramifications for retinal disease.
Press release - 04/08/2022 Inflammation accelerates aging of the hematopoietic system In mice, inflammation in early to mid-life leads to a permanent decline in functional blood stem cells, according to a recent publication by scientists from the German Cancer Research Center (DKFZ) and the Stem Cell Institute HI-STEM*. The ability of the blood stem cells to regenerate was suppressed for at least one year after challenge with inflammation.
Press release - 29/07/2022 New centre for model-based artificial intelligence A centre for model-based artificial intelligence has been set up at Heidelberg University to link mathematical modelling methods with information processing in neuronal networks. The Carl Zeiss Foundation (CZS) is funding the CZS Heidelberg Center for Model-Based AI with five million euros over a period of six years.
Press release - 29/06/2022 RNA modifications in mitochondria promote invasive spread of cancer Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.
Press release - 23/06/2022 Cancer patients receiving immunotherapy: no evidence of increased risk for severe immune complication after COVID-19 vaccination Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…
Press release - 21/06/2022 Another step towards synthetic cells Scientists from the 2. Physics Institute at the University of Stuttgart and the Max Planck Institute for Medical Research were now able to take the next step towards synthetic cells: They introduced functional DNA-based cytoskeletons into cell-sized compartments and showed functionality. The results were recently published in Nature Chemistry.
Press release - 20/06/2022 Protein changes in the liquor indicate inflammatory processes in the brain Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.